Explainable Artificial Intelligence

ModelOp Announces New Actionable Monitoring that Results in Increased Model Revenue Contribution

Retrieved on: 
Wednesday, June 30, 2021

Al/ML models are typically monitored for performance and quality issues like drift, availability, and interpretability but that is not enough.

Key Points: 
  • Al/ML models are typically monitored for performance and quality issues like drift, availability, and interpretability but that is not enough.
  • ModelOp Center's actionable monitoring also enforces risk controls and immediately initiates remediation actions.
  • Remediation actions are orchestrated to ensure model issues are fully resolved with minimal interruption to the business and resolutions are fully documented for auditability.
  • ModelOp Center automates the governance, monitoring and orchestration of AI and analytic models across platforms and teams, resulting in reliable, compliant and scalable AI initiatives.

InRule Technology® Acquires Explainable AI Software Leader, simMachines, Inc.

Retrieved on: 
Tuesday, June 8, 2021

By combining the InRule Decision Platform with simMachines explainable AI technology, enterprises can leverage the power of human-driven (declarative) and machine-driven (non-declarative) AI within a single platform.

Key Points: 
  • By combining the InRule Decision Platform with simMachines explainable AI technology, enterprises can leverage the power of human-driven (declarative) and machine-driven (non-declarative) AI within a single platform.
  • In todays market, explainable AI is essential for automating predictions and decisions in an ethical manner, said Rob Levy , a software industry expert and senior advisor to InRule.
  • The addition of simMachines explainable AI technology to InRules decision platform provides enterprises with superior visibility into automated predictions and outcomes, ensuring that AI is being used in a responsible, bias-free manner.
  • InRule and InRule Technology are registered trademarks of InRule Technology, Inc. All other trademarks and trade names mentioned herein may be the trademarks of their respective owners and are hereby acknowledged.

InRule Technology Acquires simMachines to Enhance Its Decision Automation Capabilities

Retrieved on: 
Tuesday, June 8, 2021

InRule Technology, Inc. (InRule), a market-leading digital decisioning software platform, and portfolio company of OpenGate Capital , announced today that it has acquired simMachines, a leader in explainable AI and ML technology.

Key Points: 
  • InRule Technology, Inc. (InRule), a market-leading digital decisioning software platform, and portfolio company of OpenGate Capital , announced today that it has acquired simMachines, a leader in explainable AI and ML technology.
  • The add-on acquisition of simMachines brings an immediate expansion to InRules strategic and technology capabilities.
  • We are thrilled to augment our decision platform with simMachines technology to create the most comprehensive AI solution in the market, while advancing our mission of making automation accessible across the enterprise.
  • Together, InRule and simMachines will provide extraordinary decision automation capabilities to data scientists, developers, and citizen developers alike, while delivering actionable insights that foster transparency and trust, said Chomko .

Temenos Accelerates Banking Innovation for SMEs with the launch of Temenos Virtual COO at TCF Online 2021

Retrieved on: 
Tuesday, June 1, 2021

Temenos and Canadian Western Bank (CWB) have innovated together to develop an Explainable AI-driven (XAI) solution, Temenos Virtual COO.

Key Points: 
  • Temenos and Canadian Western Bank (CWB) have innovated together to develop an Explainable AI-driven (XAI) solution, Temenos Virtual COO.
  • Following TCF Online 2021, Temenos (SIX: TEMN), the banking software company, announces that it has launched Temenos Virtual COO globally.
  • Temenos Virtual COO is built on Temenos Infinity, the leading digital banking platform, and leverages Temenos Analytics and API-first, cloud-native technology.
  • With Temenos Virtual COO, financial institutions worldwide will be able to empower SMEs with intelligent business banking and drive growth with funding innovation.

Extreme Networks Expands CoPilot's AI-Driven Capabilities to Empower Taxed Network Administrators

Retrieved on: 
Wednesday, May 26, 2021

CoPilot is designed to deliver explainable artificial intelligence (AI) insights for IT network administrators, enabling them to quickly resolve well-known but highly complex issues.

Key Points: 
  • CoPilot is designed to deliver explainable artificial intelligence (AI) insights for IT network administrators, enabling them to quickly resolve well-known but highly complex issues.
  • CoPilot provides network administrators with an AI assistant that can more easily monitor highly distributed network environments, reducing the risk of missing potential network issues and lessening time spent on network management .
  • Automatic Access for Pilot Subscribers: ExtremeCloud IQ is trusted to manage nearly 1.6 million network devices each day and counting.
  • Extreme Networks, the Extreme Networks logo, and ExtremeCloud are trademarks or registered trademarks of Extreme Networks, Inc. in the United States and other countries.

ChemoCentryx, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Retrieved on: 
Tuesday, May 11, 2021

ChemoCentryx designed the study of its Phase III ADVOCATE trial in a manner that created issues relating to the interpretability of trial data to define a clinically meaningful benefit of avacopan.

Key Points: 
  • ChemoCentryx designed the study of its Phase III ADVOCATE trial in a manner that created issues relating to the interpretability of trial data to define a clinically meaningful benefit of avacopan.
  • This trial data presented serious safety concerns in relation to avacopan.
  • Throughout the class period, ChemoCentryx's public statements were false and materially misleading based on these facts.
  • Investors suffered damages when the market learned the truth about ChemoCentryx.\nA class action lawsuit has already been filed.

ChemoCentryx, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Retrieved on: 
Friday, May 7, 2021

ChemoCentryx designed the study of its Phase III ADVOCATE trial in a manner that created issues relating to the interpretability of trial data to define a clinically meaningful benefit of avacopan.

Key Points: 
  • ChemoCentryx designed the study of its Phase III ADVOCATE trial in a manner that created issues relating to the interpretability of trial data to define a clinically meaningful benefit of avacopan.
  • This trial data presented serious safety concerns in relation to avacopan.
  • Throughout the class period, ChemoCentryx's public statements were false and materially misleading based on these facts.
  • Investors suffered damages when the market learned the truth about ChemoCentryx.\nA class action lawsuit has already been filed.

Announcing Fiddler AI's Strategic Collaboration with In-Q-Tel and Participation in FinRegLab Research

Retrieved on: 
Thursday, May 6, 2021

We\'ve been fortunate to partner with the likes of Lockheed Martin & Amazon Alexa , and are honored to continue these strategic and innovative partnerships.

Key Points: 
  • We\'ve been fortunate to partner with the likes of Lockheed Martin & Amazon Alexa , and are honored to continue these strategic and innovative partnerships.
  • Over the last few months, we\'ve been fortunate to build strong relationships with the team at In-Q-Tel & join a FinRegLab research project.
  • "Fiddler\'s platform efficiently combines both explainable AI and model monitoring in order to ensure that AI/ML systems function reliably and transparently.
  • We are thrilled to partner with Fiddler in helping our government partners better manage and monitor their AI/ML capabilities.

BlueShore Financial Expands Relationship with Temenos to Further its Digital Transformation

Retrieved on: 
Tuesday, April 13, 2021

b'Temenos (SIX: TEMN), the banking software company, today announced that BlueShore Financial, a boutique full service financial institution, is digitally transforming with Temenos.

Key Points: 
  • b'Temenos (SIX: TEMN), the banking software company, today announced that BlueShore Financial, a boutique full service financial institution, is digitally transforming with Temenos.
  • Powered by Temenos Infinity, the market-leading omnichannel digital banking product, BlueShore will extend its \xe2\x80\x98HighTech-HighTouch\xe2\x80\x99 experience to clients by leveraging explainable artificial intelligence (XAI).
  • The expansion of the relationship to include the full Temenos Infinity digital platform, Temenos Data Lake , Temenos Explainable AI (XAI) and Temenos Payments will take this further, as BlueShore executes a data-driven, cutting-edge digital strategy.\nBlueShore has been a long-standing Temenos partner, using Temenos Transact to create a high-performing cost-efficient core banking environment.
  • BlueShore Financial is the operating name of BlueShore Financial Credit Union.\nTemenos AG (SIX: TEMN) is the world\xe2\x80\x99s leader in banking software.

Fujitsu, Kyoto University Develop Explainable AI Verification System for Estimating Disease-Causing Potential of Genetic Mutations

Retrieved on: 
Thursday, March 11, 2021

In addition to the pathogenicity estimation AI, the MGeND Intelligence verification system includes explainable AI that shows the basis of the system's findings, as well as literature search AI that supports the retrieval of related articles.

Key Points: 
  • In addition to the pathogenicity estimation AI, the MGeND Intelligence verification system includes explainable AI that shows the basis of the system's findings, as well as literature search AI that supports the retrieval of related articles.
  • Genetic mutations with unknown pathogenicity present a challenge in that they do not provide useful information for treating disease.
  • Fujitsu and Kyoto University have now developed an AI system that can estimate the presence or absence of disease causing potential for unknown genetic mutations and explain the basis for this finding.
  • "MGeND Intelligence" is a verification system jointly developed by Fujitsu and Kyoto University, designed to support researchers studying genetic mutations.